Precision Epigenomics

Precision Epigenomics has launched the EPISEEK™ liquid biopsy test for multi-cancer early detection using a proprietary panel of epigenetic/methylation markers validated on thousands of tumor samples. The assay detects more than twenty solid tumors with a single blood draw. Clinical abstracts show high sensitivity/specificity in melanoma and promising pilot results in glioblastoma. The company operates a CLIA-certified lab and has begun commercial sales to US/international markets targeting self-pay patients via functional/integrative medicine practices. Ongoing studies are expanding the evidence base for new indications including minimal residual disease monitoring and therapy response assessment.